BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumar A, Srivastava DN, Chau TT, Long HD, Bal C, Chandra P, Chien le T, Hoa NV, Thulkar S, Sharma S, Tam le H, Xuan TQ, Canh NX, Pant GS, Bandopadhyaya GP. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial. Radiology 2007;243:509-19. [PMID: 17456873 DOI: 10.1148/radiol.2432051246] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol 2014;4:S112-21. [PMID: 25755602 DOI: 10.1016/j.jceh.2014.03.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
2 Maccauro M, Lorenzoni A, Boni G, Chiesa C, Spreafico C, Romito R, Mazzaferro V, Seregni E. Multiagent imaging of liver tumors with reference to intra-arterial radioembolization. Clin Transl Imaging 2013;1:423-32. [DOI: 10.1007/s40336-013-0040-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Mallia MB, Chirayil V, Dash A. Improved freeze-dried kit for the preparation of 188ReN-DEDC/lipiodol for the therapy of unresectable hepatocellular carcinoma. Appl Radiat Isot 2018;137:147-53. [PMID: 29625347 DOI: 10.1016/j.apradiso.2018.03.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
4 Radhakrishnan ER, Chirayil V, Pandiyan A, Subramanian S, Mallia MB, Kamaleshwaran KK, Shinto A. Preparation of Rhenium-188-Lipiodol Using Freeze-Dried Kits for Transarterial Radioembolization: An Overview and Experience in a Hospital Radiopharmacy. Cancer Biother Radiopharm 2021. [PMID: 34101501 DOI: 10.1089/cbr.2021.0043] [Reference Citation Analysis]
5 Chiang P, Peng C, Shih Y, Cho Y, Yu C, Kuo Y, Shieh M, Luo T. Biodegradable and Multifunctional Microspheres for Treatment of Hepatoma through Transarterial Embolization. ACS Biomater Sci Eng 2018;4:3425-33. [DOI: 10.1021/acsbiomaterials.8b00635] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol. 2011;21:294-302. [PMID: 21939859 DOI: 10.1016/j.semradonc.2011.05.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
7 Riaz A, Lewandowski RJ, Salem R. Locoregional Therapies for Primary and Secondary Hepatic Malignancies. In: Bentrem D, Benson AB, editors. Gastrointestinal Malignancies. Cham: Springer International Publishing; 2016. pp. 233-56. [DOI: 10.1007/978-3-319-34244-3_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Ferro-Flores G, Arteaga de Murphy C. Pharmacokinetics and dosimetry of 188 Re-pharmaceuticals. Adv Drug Deliv Rev 2008;60:1389-401. [PMID: 18547675 DOI: 10.1016/j.addr.2008.04.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
9 Lepareur N, Lacœuille F, Bouvry C, Hindré F, Garcion E, Chérel M, Noiret N, Garin E, Knapp FFR Jr. Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives. Front Med (Lausanne) 2019;6:132. [PMID: 31259173 DOI: 10.3389/fmed.2019.00132] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 11.7] [Reference Citation Analysis]
10 Tajiri K, Futsukaichi Y, Kobayashi S, Nagata K, Yasumura S, Takahara T, Minemura M, Yasuda I. Efficacy of on-demand intrahepatic arterial therapy in combination with sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2019;12:2205-14. [PMID: 30988625 DOI: 10.2147/OTT.S191741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Luo TY, Shih YH, Chen CY, Tang IC, Wu YL, Kung HC, Lin WJ, Lin XZ. Evaluating the potential of (188)Re-ECD/lipiodol as a therapeutic radiopharmaceutical by intratumoral injection for hepatoma treatment. Cancer Biother Radiopharm 2009;24:535-41. [PMID: 19877883 DOI: 10.1089/cbr.2008.0603] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
12 Vanpouille-Box C, Lacoeuille F, Roux J, Aubé C, Garcion E, Lepareur N, Oberti F, Bouchet F, Noiret N, Garin E. Lipid nanocapsules loaded with rhenium-188 reduce tumor progression in a rat hepatocellular carcinoma model. PLoS One. 2011;6:e16926. [PMID: 21408224 DOI: 10.1371/journal.pone.0016926] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
13 Wáng YX, De Baere T, Idée JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015;27:96-121. [PMID: 25937772 DOI: 10.3978/j.issn.1000-9604.2015.03.03] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
14 Paul SB, Gamanagatti S, Sreenivas V, Chandrashekhara SH, Mukund A, Gulati MS, Gupta AK, Acharya SK. Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India. Indian J Radiol Imaging. 2011;21:113-120. [PMID: 21799594 DOI: 10.4103/0971-3026.82294] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
15 Madhusudhan KS, Srivastava DN, Sharma S, Sharma S. Interventional Radiology in India. American Journal of Roentgenology 2018;211:730-5. [DOI: 10.2214/ajr.18.19777] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Kim DY, Han KH. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. Hepatol Int 2016;10:883-92. [PMID: 27126821 DOI: 10.1007/s12072-016-9722-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
17 Bouvry C, Palard X, Edeline J, Ardisson V, Loyer P, Garin E, Lepareur N. Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres. Biomed Res Int 2018;2018:1435302. [PMID: 30687734 DOI: 10.1155/2018/1435302] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
18 Zhang Y, Fan W, Zhu K, Lu L, Fu S, Huang J, Wang Y, Yang J, Huang Y, Yao W, Li J. Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response. Oncotarget 2015;6:24550-9. [PMID: 26093084 DOI: 10.18632/oncotarget.4076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
19 Zhang Y, Fan W, Wang Y, Lu L, Fu S, Yang J, Huang Y, Yao W, Li J. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. Oncologist. 2015;20:1417-1424. [PMID: 26446238 DOI: 10.1634/theoncologist.2015-0196] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
20 Idée JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol. 2013;88:530-549. [PMID: 23921081 DOI: 10.1016/j.critrevonc.2013.07.003] [Cited by in Crossref: 107] [Cited by in F6Publishing: 93] [Article Influence: 11.9] [Reference Citation Analysis]
21 Nowicki ML, Cwikla JB, Sankowski AJ, Shcherbinin S, Grimmes J, Celler A, Buscombe JR, Bator A, Pech M, Mikołajczak R, Pawlak D. Initial study of radiological and clinical efficacy radioembolization using 188Re-human serum albumin (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancers. Med Sci Monit 2014;20:1353-62. [PMID: 25086245 DOI: 10.12659/MSM.890480] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
22 Shih YH, Lin XZ, Yeh CH, Peng CL, Shieh MJ, Lin WJ, Luo TY. Preparation and therapeutic evaluation of (188)Re-thermogelling emulsion in rat model of hepatocellular carcinoma. Int J Nanomedicine 2014;9:4191-201. [PMID: 25214783 DOI: 10.2147/IJN.S66346] [Reference Citation Analysis]
23 Subramanian S, Pandey U, Chaudhari P, Tyagi M, Gupta S, Singh G, Dash A, Samuel G, Venkatesh M. Preliminary evaluation of indigenous 90 Y-labelled microspheres for therapy of hepatocellular carcinoma. Indian J Med Res 2016;143:S74-81. [PMID: 27748281 DOI: 10.4103/0971-5916.191786] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
24 Liu Y, Yang R. Preoperative Combined with Postoperative Chemoembolization Can Improve Survival in Patients with Hepatocellular Carcinoma: A Single-center Study. Journal of Vascular and Interventional Radiology 2009;20:472-83. [DOI: 10.1016/j.jvir.2009.01.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
25 Pleguezuelo M, Germani G, Marelli L, Xiruochakis E, Misseri M, Manousou P, Arvaniti V, Burroughs AK. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;2:761-84. [DOI: 10.1586/17474124.2.6.761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
26 Ma S, Jiao B, Liu X, Yi H, Kong D, Gao L, Zhao G, Yang Y, Liu X. Approach to radiation therapy in hepatocellular carcinoma. Cancer Treat Rev 2010;36:157-63. [PMID: 20031332 DOI: 10.1016/j.ctrv.2009.11.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
27 Padia SA, Lewandowski RJ, Johnson GE, Sze DY, Ward TJ, Gaba RC, Baerlocher MO, Gates VL, Riaz A, Brown DB, Siddiqi NH, Walker TG, Silberzweig JE, Mitchell JW, Nikolic B, Salem R. Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. Journal of Vascular and Interventional Radiology 2017;28:1-15. [DOI: 10.1016/j.jvir.2016.09.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
28 Andreana L, Isgrò G, Marelli L, Davies N, Yu D, Navalkissoor S, Burroughs AK. Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: trans-arterial radio-embolisation of HCC. Cancer Treat Rev. 2012;38:641-649. [PMID: 22169503 DOI: 10.1016/j.ctrv.2011.11.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
29 Wu J, Li A, Yang J, Lu Y, Li J. Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study. Onco Targets Ther 2017;10:2761-8. [PMID: 28603426 DOI: 10.2147/OTT.S131022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
30 Vanpouille-Box C, Hindré F. Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity. Front Oncol 2012;2:136. [PMID: 23087900 DOI: 10.3389/fonc.2012.00136] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
31 Raoul JL, Edeline J, Pracht M, Boucher E, Rolland Y, Garin E. [Radioembolisation for hepatocellular carcinoma]. Cancer Radiother 2011;15:64-8. [PMID: 21236718 DOI: 10.1016/j.canrad.2010.12.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Tan HY, Yeong CH, Wong YH, McKenzie M, Kasbollah A, Md Shah MN, Perkins AC. Neutron-activated theranostic radionuclides for nuclear medicine. Nucl Med Biol 2020;90-91:55-68. [PMID: 33039974 DOI: 10.1016/j.nucmedbio.2020.09.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Ibrahim SM, Lewandowski RJ, Sato KT, Gates VL, Kulik L, Mulcahy MF, Ryu RK, Omary RA, Salem R. Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review. World J Gastroenterol 2008; 14(11): 1664-1669 [PMID: 18350597 DOI: 10.3748/wjg.14.1664] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
34 Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JI, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrel M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson AB 3rd, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A; Technology Assessment Committee., Interventional Oncology Task Force of the Society of Interventional Radiology. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 2011;22:265-78. [PMID: 21353979 DOI: 10.1016/j.jvir.2010.10.029] [Cited by in Crossref: 148] [Cited by in F6Publishing: 140] [Article Influence: 13.5] [Reference Citation Analysis]
35 Subramanian S, Das T, Chakraborty S, Sarma HD, Banerjee S, Samuel G, Venkatesh M. Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: a preliminary animal study. Cancer Biother Radiopharm 2010;25:539-43. [PMID: 20849309 DOI: 10.1089/cbr.2010.0792] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
36 Raoul JL, Boucher E, Rolland Y, Garin E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat Rev Gastroenterol Hepatol 2010;7:41-9. [PMID: 20051971 DOI: 10.1038/nrgastro.2009.202] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
37 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]